FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, namely to cardiology and can be used for connective tissue density correction following myocardial infarction and pericardiotomy. The method involves triple administration of an inhibitor of a polypeptide sequence containing fragments -Asp-Pro-Lys-Arg-Leu-Tyr-Cys-Asn-Gly-Gly-, -Glu-Arg-Gly-Val-Val-Ser-Ile-Lys-Gly- and -Ala-Asn-Arg-Tyr-Leu-Ala-Met-Lys-Glu-Asp-Gly-Arg-Leu- and having 100 to 240 amino-acid residues in 1.5 and 6 hours and in 3 days after infarction and pericardiotomy started.
EFFECT: use of the invention allows restructuring the forming connective tissue due to changing of the polypeptide sequence concentration in certain distances of a pathological process and thereby reducing fibrosis following myocardial infarction and pericardiotomy.
4 cl, 2 tbl, 5 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CORRESPONDING TARGET FOR TREATING FIBROSING DISEASES AND USE THEREOF | 2021 |
|
RU2830698C1 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2019 |
|
RU2728861C1 |
| TREATMENT OF ABNORMAL VISCERAL FAT DEPOSITION WITH FIBROBLAST GROWTH FACTOR 3 (sFGFR3) SOLUBLE POLYPEPTIDES | 2018 |
|
RU2794170C2 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2012 |
|
RU2698655C2 |
| IMMUNOGLOBULIN WITH TANDEM ARRANGEMENT OF FAB FRAGMENTS AND APPLICATION THEREOF | 2014 |
|
RU2769133C2 |
| FUSED SERPINE POLYPEPTIDES AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2746550C2 |
| COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS OF CALCIFICATION AND THEIR APPLICATION METHODS | 2016 |
|
RU2757417C2 |
| POLYSPECIFIC POLYPEPTIDE CONSTRUCTS WITH LIMITED BINDING TO CD3 AND METHODS OF THEIR APPLICATION | 2018 |
|
RU2813816C2 |
| TGF-BETA RECEPTOR ECTODOMAIN FUNCTIONS AND THEIR USE | 2018 |
|
RU2797464C2 |
| FGFR2 INHIBITORS SEPARATELY OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN CANCER TREATMENT | 2016 |
|
RU2745707C2 |
